Drug Trial Radar · NCT02004691
Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Last checked: Nov 20, 2026Latest source record: Nov 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Dec 18, 2015
Primary completion
Mar 15, 2021
Study completion Oct 19, 2023
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 9, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary Objective: The primary objective of this phase 2/3 study was to evaluate the efficacy of olipudase alfa (recombinant human acid sphingomyelinase) administered intravenously once every 2 weeks for 52 weeks in adult participants with acid sphingomyelinase deficiency (ASMD) by assessing changes in: 1) spleen volume as measured by abdominal magnetic resonance imaging (MRI) (and, for the United States \[US\] only, in association with participant perception related to spleen volume as measured by splenomegaly-related score \[SRS\]); and 2) infiltrative lung disease as measured by the pulmonary function test, diffusing capacity of the lung for carbon monoxide (DLCO). Secondary Objectives: * To confirm the safety of olipudase alfa administered intravenously once every 2 weeks for 52 weeks. * To characterize the effect of olipudase alfa on the participant perception related to spleen volume as measured by the SRS after 52 weeks of study drug administration. (For the US, the effect of olipudase alfa on the SRS is part of the primary objective). * To characterize the effect of olipudase alfa after 52 weeks of study drug administration on the following outcome measures assessed sequentially: * The effect of olipudase alfa on liver volume; * The effect of olipudase alfa on platelet count; * The effect of olipudase alfa on fatigue; * The effect of olipudase alfa on pain; * The effect of olipudase alfa on dyspnea.
Conditions
- Sphingomyelin Lipidosis
Interventions
placebo (saline)Drug
Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to placebo. Route of administration: intravenous infusion
Olipudase alfaDrug
Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to olipudase alfa, and during the extension treatment period for all participants. Route of administration: intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Predicted (% Predicted) Hemoglobin (Hb) and Altitude-Adjusted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) at BaselineTime frame: Baseline (Day 1)
- Percent Change From Baseline in Percent Predicted (% Predicted) Hemoglobin (Hb) and Altitude-Adjusted Diffusing Capacity of the Lung for Carbon Monoxide (DLco) at Week 52Time frame: Baseline, Week 52
- Combination Spleen Endpoint: Component 1: Spleen Volume (in MN) at BaselineTime frame: Baseline (Day 1)
- Combination Spleen Endpoint: Component 1: Percent Change From Baseline in Spleen Volume (in MN) at Week 52Time frame: Baseline, Week 52
- Combination Spleen Endpoint (Primary for US Only): Component 2: Splenomegaly-Related Score (SRS) at BaselineTime frame: Baseline (Day 1)
- Combination Spleen Endpoint (Primary for US Only): Component 2: Change From Baseline in Splenomegaly-Related Score (SRS) at Week 52Time frame: Baseline, Week 52
Locations
24 sites in 17 countries. Site status is shown where the registry gives one.
UCSF Medical Center Site Number : 840005
San Francisco, California
Emory University Site Number : 840003
Decatur, Georgia
Montefiore Medical Center Site Number : 840006
The Bronx, New York
Investigational Site Number : 032001
Córdoba, Argentina
Investigational Site Number : 036001
Westmead, New South Wales, Australia
Investigational Site Number : 056001
Leuven, Belgium
Hospital De Clinicas De Porto Alegre Site Number : 076001
Porto Alegre, Rio Grande do Sul, Brazil
Investigational Site Number : 100001
Sofia, Bulgaria
Investigational Site Number : 152001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 250001
Paris, France
Investigational Site Number : 276001
Mainz, Germany
Investigational Site Number : 380002
Naples, Italy
Investigational Site Number : 380001
Udine, Italy
Investigational Site Number : 392001
Fukushima, Fukushima, Japan
Investigational Site Number : 528001
Amsterdam, Netherlands
Investigational Site Number : 620002
Porto, Portugal
Investigational Site Number : 724001
Madrid, Spain
Investigational Site Number : 788001
Tunis, Tunisia
Investigational Site Number : 792002
Ankara, Turkey (Türkiye)
Investigational Site Number : 792004
Istanbul, Turkey (Türkiye)
Investigational Site Number : 792003
Istanbul, Turkey (Türkiye)
Investigational Site Number : 792001
Izmir, Turkey (Türkiye)
Investigational Site Number : 826002
Birmingham, United Kingdom
Investigational Site Number : 826001
London, London, City of, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.